John has made over 4 trades of the Adaptimmune Therapeutics Plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 6,723 units of ADAP stock worth $334,402 on 20 April 2018.
The largest trade he's ever made was exercising 20,000 units of Adaptimmune Therapeutics Plc stock on 12 April 2018 worth over $994,800. On average, John trades about 2,858 units every 9 days since 2016. As of 20 April 2018 he still owns at least 6,723 units of Adaptimmune Therapeutics Plc stock.
You can see the complete history of Mr. Furey stock trades at the bottom of the page.
John P. Furey serves as Non-Executive Independent Director of the Company. He also serves as a member of our Remuneration Committee. He has 25 years of experience of developing and implementing operational strategies and leading commercial and technical teams. Mr. Furey served as Chief Operating Officer at Spark Therapeutics, Inc from December 1, 2016 through December 31, 2018, where he was responsible for global commercial operations, medical affairs, technology development and technical operations, and is continuing to provide consulting services to Spark Therapeutics through June 28, 2019 to assist with the transition of his responsibilities. Prior to joining Spark Therapeutics, Mr. Furey was senior vice president and head of global operations for Baxalta, where he directed manufacturing, quality, engineering, and process development. He actively managed a $2.5 billion production budget across Baxalta's global network and led a first-in-class supply chain organization for rare diseases. Mr. Furey led the team that coordinated and delivered the successful establishment of Baxalta through a spin out from Baxter and led the Baxter Vaccine inline business to realize significant top line and bottom line growth. He also spent two years in China as general manager of Pfizer's vaccine business unit following a role with responsibility for global pricing and reimbursement at Pfizer Vaccines. In these roles, Mr. Furey gained extensive experience in pipeline development and global product launches. Earlier in his career, he held both commercial and operations positions of increasing scope and responsibility with Pfizer and Wyeth Pharmaceuticals. Mr. Furey has an executive M.B.A. from St. Joseph's University, Philadelphia, a B.S. from Trinity College, Dublin, and a diploma in Environmental Health from the Dublin Institute of Technology.
John Furey is 55, he's been the Non-Executive Independent Director of Adaptimmune Therapeutics Plc since 2018. There are 7 older and 10 younger executives at Adaptimmune Therapeutics Plc. The oldest executive at Adaptimmune Therapeutics Plc is Lawrence Alleva, 70, who is the Non-Executive Independent Director.
John's mailing address filed with the SEC is 3737 Market St #1300, Philadelphia, PA 19104, USA.
Over the last 9 years, insiders at Adaptimmune Therapeutics Plc have traded over $40,532,026 worth of Adaptimmune Therapeutics Plc stock and bought 384,338,252 units worth $527,131,726 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Adaptimmune Therapeutics Plc executives and independent directors trade stock every 20 days with the average trade being worth of $2,827,332. The most recent stock trade was executed by Cintia Piccina on 18 June 2024, trading 24,531 units of ADAP stock currently worth $22,814.
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Adaptimmune Therapeutics Plc executives and other stock owners filed with the SEC include: